New hope for kids with tough neuroblastoma? trial tests stronger therapies
NCT ID NCT03165292
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested two stronger treatment plans for children with very high risk neuroblastoma whose cancer did not respond well to initial chemotherapy. The treatments combined radioactive therapy (mIBG), chemotherapy drugs (topotecan and thiotepa), and a stem cell transplant. The goal was to see if these intensified approaches could improve survival. However, the trial was terminated early after enrolling only 34 participants, so the results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mIBG (radioactive iodine), topotecan, thiotepa, and autologous stem cell transplant
What this could lead to
If successful, this could offer a more effective treatment option for children with very high risk neuroblastoma who have a poor response to initial chemotherapy.
What could go wrong
This trial was terminated early with only 34 participants, so results are limited. The treatments involve high-dose chemotherapy and radiation, which carry significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VERY HIGH RISK NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Istituto nazionaleTumori
Milan, 20133, Italy
-
Gustave Roussy
Villejuif, Val De Marne, 94805, France
-
Hospital Universitario Cruces
Cruces, 48903, Spain
-
Hospital Universitario y policnico La Fe
Valencia, 46026, Spain
-
Medizinische Universität Innsbruck
Innsbruck, 356020, Austria
-
Meyer children's Hospita
Florence, 50139, Italy
-
Ospedale Pediatrico Bambino Gesù
Roma, Italy
-
Princess Maxima Center
Utrecht, Netherlands
-
St. Anna Kinderspital GmbH
Vienna, 1090, Austria